Jenburkt Pharmaceuticals (BOM:524731) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


BOM:524731 Jenburkt Pharmaceuticals Ltd BOM:524731
81 GF Score
Price ₹1,116.30
GF Value ₹1,112.47
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Jenburkt Pharmaceuticals Research & Development?

Jenburkt Pharmaceuticals BOM:524731 -0.77% 81 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:524731 with a GF Score™ of 81/100 and a GF Value™ of ₹1,112.47 (Fairly Valued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Jenburkt Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Jenburkt Pharmaceuticals  (BOM:524731) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Jenburkt Pharmaceuticals Research & Development Related Terms

Jenburkt Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Jenburkt Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jenburkt Pharmaceuticals Research & Development Chart

Jenburkt Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.81 12.26 12.32 4.34 0.00

Jenburkt Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:524731
81GF Score
Jenburkt Pharmaceuticals Ltd BOM:524731
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jenburkt Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Jenburkt Pharmaceuticals (BOM:524731) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Jenburkt Pharmaceuticals and its competitors.
Is Jenburkt Pharmaceuticals' Research & Development too high?
Jenburkt Pharmaceuticals' current Research & Development is ₹0 Mil. Overall, Jenburkt Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jenburkt Pharmaceuticals' Research & Development compare to ZTS and UTHR?
Jenburkt Pharmaceuticals' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Jenburkt Pharmaceuticals and its competitors. Jenburkt Pharmaceuticals's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenburkt Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals (BOM:524731) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,112.47, compared to a current price of ₹1,116.30 — trading 0.3% above its estimated fair value. The current Research & Development is ₹0 Mil. Jenburkt Pharmaceuticals' overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Jenburkt Pharmaceuticals (BOM:524731), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jenburkt Pharmaceuticals (BOM:524731) Overvalued in 2026?

Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be overvalued. The current stock price of ₹1,116.30 is trading 0.3% above its estimated GF Value™ of ₹1,112.47. GuruFocus considers Jenburkt Pharmaceuticals to be Fairly Valued.

Key valuation signals for BOM:524731:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹1,112.47 vs. price of ₹1,116.30 (0.3% above fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the BOM:524731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jenburkt Pharmaceuticals Business Description

Address 93, Jayprakash Road, Nirmala Apartments, Andheri (West, Mumbai, MH, IND, 400058
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
81GF Score

Get the complete analysis for BOM:524731

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,116.30
Price
₹1,112.47
GF Value